Clinical Trial: NCT05285943
Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients
Status:
COMPLETEDPhase:
Phase 4| Lead Sponsor: | Cairo University |
| Information Provided By: | Cairo University |
| Last Update Posted: | 2025-02-12 |
Study Overview
Brief Summary
This study aims to compare the prophylactic effect of topical betamethasone valerate cream and topical olive oil cream in the prevention of acute radiation dermatitis (ARD) in breast cancer patients treated with radiation. Betamethasone valerate, olive oil cream and the base cream will be compared in a randomized trial to evaluate and compare the development and degree of ARD grading according to Radiation Toxicity Grading (RTOG) skin toxicity score, percentage of patients with the maximum observed ARD grade for each arm of the study, percentage of patients with moist desquamation for each arm of the study, percentage of radiodermatitis-free patients at end of therapy (EOT=time point specifically at end of 2 weeks post radiation therapy). In addition, the patients' quality of life will be evaluated using Dermatology Life Quality Index (DLQI).
Official Title
Conditions
Intervention / Treatment
- Drug: Olive oil cream
- Drug: Betamethasone Valerate Cream
- Other: Base Cream
Other Study ID Numbers
- CL 2775
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Cairo University |
| Information Provided By: | Cairo University |
| Last Update Posted: | 2025-02-12 |
Study Overview
Brief Summary
This study aims to compare the prophylactic effect of topical betamethasone valerate cream and topical olive oil cream in the prevention of acute radiation dermatitis (ARD) in breast cancer patients treated with radiation. Betamethasone valerate, olive oil cream and the base cream will be compared in a randomized trial to evaluate and compare the development and degree of ARD grading according to Radiation Toxicity Grading (RTOG) skin toxicity score, percentage of patients with the maximum observed ARD grade for each arm of the study, percentage of patients with moist desquamation for each arm of the study, percentage of radiodermatitis-free patients at end of therapy (EOT=time point specifically at end of 2 weeks post radiation therapy). In addition, the patients' quality of life will be evaluated using Dermatology Life Quality Index (DLQI).
Official Title
Conditions
Intervention / Treatment
- Drug: Olive oil cream
- Drug: Betamethasone Valerate Cream
- Other: Base Cream
Other Study ID Numbers
- CL 2775